Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: Subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)

David Miles, José Baselga, Dino Amadori, Patrapim Sunpaweravong, Vladimir Semiglazov, Adam Knott, Emma Clark, Graham Ross, Sandra M. Swain

Research output: Contribution to journalArticle

Abstract

Although the incidence of cancer increases with age, older patients are under-represented in cancer treatment trials, resulting in limited data availability in this patient population. Here we present results from pre-defined subgroup analyses conducted by age group (

Original languageEnglish
Pages (from-to)89-99
Number of pages11
JournalBreast Cancer Research and Treatment
Volume142
Issue number1
DOIs
Publication statusPublished - Nov 2013

Keywords

  • Elderly
  • HER2
  • Metastatic breast cancer
  • Older women
  • Pertuzumab
  • Trastuzumab

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: Subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)'. Together they form a unique fingerprint.

  • Cite this